References
- Bousquet, J, Van Cauwenberge, P, Khaltaev, N, Aria Workshop Group and World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108:s147–s334.
- Meltzer EO, Nathan RA, Selner JC. Quality of life and rhinitic symptoms: results of a nationwide survey with the SF-36 and RQLQ questionnaires. J Allergy Clin Immunol 1997; 99: s815–s819
- Thompson AK, Juniper E, Meltzer EO. Quality of life in patients with allergic rhinitis. Ann Allergy Asthma Immunol 2000; 85: 338–48
- Juniper EF, Rohrbaugh T, Meltzer EO. A questionnaire to measure quality of life in adults with nocturnal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2003; 111: 484–90
- Juniper EF. Measuring health-related quality of life in rhinitis. J Allergy Clin Immunol 1997; 99: s742–s749
- Young, T, Finn, L, Kim, H, for the University of Wisconsin Sleep and Respiratory Research Group. Nasal obstruction as a risk factor for sleep-disordered breathing. J Allergy Clin Immunol 1997;99:s757–s762.
- Herman H. Once-daily administration of intranasal corticosteroids for allergic rhinitis: a comparative review of efficacy, safety, patient preference, and cost. Am J Rhinol 2007; 21: 70–9
- Mygind N, Andersson M. Topical glucocorticosteroids in rhinitis: clinical aspects. Acta Otolaryngol 2006; 126: 1022–9
- Craig TJ, Teets S, Lehman EB, Chinchilli VM, Zwillich C. Nasal congestion secondary to allergic rhinitis as a cause of sleep disturbance and daytime fatigue and the response to topical nasal corticosteroids. J Allergy Clin Immunol 1998; 101: 633–7
- Pitsios C, Papadopoulos D, Kompoti E, Manoussakis E, Garris V, Petalas K, et al. Efficacy and safety of mometasone furoate vs nedocromil sodium as prophylactic treatment for moderate/severe seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2006; 96: 673–8
- Lange B, Lukat KF, Rettig K, Holtappels G, Bachert C. Efficacy, cost-effectiveness, and tolerability of mometasone furoate, levocabastine, and disodium cromoglycate nasal sprays in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2005; 95: 272–82
- Patel RS, Shaw SR, Wallace AM, McGarry GW. Efficacy and systemic tolerability of mometasone furoate and betamethasone sodium phosphate. J Laryngol Otol 2004; 118: 866–71
- Juniper EF, Thompson AK, Ferrie PJ, Roberts JN. Development and validation of the mini Rhinoconjunctivitis Quality of Life of Questionnaire. Clin Exp Allergy 2000; 30: 132–40
- Juniper EF, Rohrbaugh T, Meltzer EO. A questionnaire to measure quality of life in adults with nocturnal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2003; 111: 484–90
- Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy 2008; 63(86 Suppl)8–160
- Berkowitz RB, Bernstein DI, LaForce C, Pedinoff AJ, Rooklin AR, Damaraju CR, et al. Onset of action of mometasone furoate nasal spray (NASONEX) in seasonal allergic rhinitis. Allergy 1999; 54: 64–9
- Ciprandi G, Canonica WG, Grosclaude M, Ostinelli J, Brazzola GG, Bousquet J. Effects of budesonide and fluticasone propionate in a placebo-controlled study on symptoms and quality of life in seasonal allergic rhinitis. Allergy 2002; 57: 586–91